SynOV1.1
AXP000045.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, AFP-responsive synthetic gene circuit)
- Originator
- Beijing Syngentech
- Sponsor
- Beijing Syngentech
Names
| Name | Type | Source |
|---|---|---|
| SynOV1.1 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (SynOV1.1)
- Replication
- conditionally replicating
- Modifications
- synthetic gene circuit restricting replication and transgene expression to AFP-positive cells
- Transgenes
- CSF2
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C179256
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04612504 | SynOV1.1 Intratumoral Injection Study | Unknown | Phase 1 | 2022-06-23 | 2023-12-30 | 15 | Hepatocellular Carcinoma |
Recent changes
No changes recorded in its trials yet.
Notes
Oncolytic adenovirus with a synthetic gene circuit that restricts replication and GM-CSF expression to alpha-fetoprotein-positive cancer cells. Phase I NCT04612504 in AFP-positive hepatocellular carcinoma.
How to cite
SynOV1.1 (AXP000045.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000045.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.